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LETTERS TO THE EDITOR
Nifedipine Versus Isosorbide Dinitrate in
Patients With Exertional Angina
Receiving Propranolol
Morse and Nesto (I) have reported that the combination of nifed-
ipine and propranolol is more effective than the combination of
isosorbide dinitrate and propranolol in reducing the incidence of
angina and improving exercise performance. It would be unfor-
tunate if these unwarranted conclusions were to go unchallenged.
Their study clearly demonstrates that when a serious flaw exists
in the basic design, "double-blind crossover comparison" may
afford little justification for drawing sweeping conclusions. In real-
ity, what Morse and Nesto appear to have shown is that maximal
doses of nifedipine to the limits of tolerance are superior to minimal
or relatively low doses of isosorbide dinitrate when these agents
are used in combination with propranolol. The disparity in the
dosage range chosen for the respective drugs is unwittingly made
clear by the authors in their statement that" although only 4 patients
could tolerate the maximal dose of 120 mg/day of nifedipine, 14
tolerated the maximal dose of 120 mg/day of isosorbide dinitrate."
Thus, of the 27 patients with exertional angina in the study, 13
received four daily doses of isosorbide amounting to 20 mg or less
per dose and of these, 7 actually received only 10 mg of the drug
with the same frequency. In three cases, the lowest dose of iso-
sorbide dinitrate (10 mg, four times daily) caused intolerable head-
aches so that premature termination of treatment or crossover to
nifedipine therapy was the final resort. Obviously, such hyper-
sensitivity to the nitrates should have eliminated these subjects
from the study at the outset because their inclusion only served to
bias the results in favor of nifedipine.
The data therefore indicate that only 14 patients of the 27
in the series received isosorbide dinitrate orally in a dosage of
30 mg four times daily. By today's standards even this represents
only a modest amount of the drug, inadequate for optimal thera-
peutic response. For many years the dosage of oral nitrates was
set by arbitrary means and not by careful observation and titration
in human subjects. Through experience, older clinicians recog-
nized that when nitrates are administered by the oral route there
is an attenuation of effect as compared with the responses following
sublingual administration. This loss in potency was known to
encompass all orally administered nitrate compounds and is now
attributed to enzymatic degradation in the liver before drug action
at cardiovascular target sites. To overcome this nullifying influence
and to approach responses possible with sublingual nitrates, in-
ordinately high doses were found to be essential by the oral route.
The long use of "homeopathic" and other ineffectual doses of
oral nitrates has had a "carryover" effect in retarding wide rec-
ognition of therapeutic benefits to be derived from dosage levels
extending to the limits of tolerance.
Despite these considerations, sublingual nitrates are far more
potent than oral nitrates even in massive dosage for the treatment
of stable angina pectoris. Moreover, the additive and often syn-
ergistic response observed when sublingual isosorbide dinitrate is
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used in conjunction with a beta-blocker (2) is a unique phenomenon
that has not been matched to date by any combination of beta-
blocker and calcium channel blocker (3). Until this is fully rec-
ognized, many patients with stable angina are destined to be de-
prived of optimal therapy for this disorder.
A final comment appears indicated concerning the cost of drug
therapy. Nifedipine alone in the dosage range employed by Morse
and Nesto would require an expenditure by the patient of $650 to
$1,000 a year. Isosorbide dinitrate orally (Tembids, 40 mg, four
times daily) or sustained release nitroglycerin (6.5 mg, four times
daily) would cost the patient $100 to $128 for I year's supply.
For the same period of time, sublingual isosorbide dinitrate (5 mg,
four times daily) would cost $56 and a beta-blocker about $152.
In other words, the outlay for nifedipine alone for I year would
amount to two to three times the combined cost of a beta-blocker,
oral nitrate and sublingual isosorbide dinitrate for the same interval
($650 to $1,000 versus $336). From the evidence, the increased
expenditure for nifedipine does not at this time appear warranted
for the treatment of stable angina pectoris responsive to standard
therapy.
HENRY I. RUSSEK,MD,FACC
1 North Ocean Road
Boca Raton, Florida 33432
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Reply
We clearly recognize that nearly half the patients in our study
group probably did not receive what is commonly regarded as
"maximal" nitrate therapy and that those who were advanced to
maximal therapy, as defined in our protocol, may very well have
tolerated even higher dosages. It is for exactly these reasons that
the dosage schedules for individual patients were painstakingly
displayed.
Those patients who received "minimal or relatively low dos-
ages" of isosorbide dinitrate were given those low dosages because
of reported side effects that prevented further upward dose titration.
In a study that is rigidly double-blinded, the investigator (unlike
the experienced clinician) does not have the luxury to interpret as
well as monitor adverse effects and thereby may not confidently
reassure patients that these (adverse effects) will likely subside
with higher doses. For the same reasons, the three patients who
were prematurely crossed over or terminated were allowed to do
so because they simply would not take the drug. We would be
subject to enormous criticism had we, in such a blinded setting,
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assumed that the "headaches" were nitrate-induced and proceeded
to encourage patients to persevere through the initial phases of
therapy. Furthermore, the side effects requiring crossover or ter-
mination were not judged to be "hypersensitivity" to nitrates
because a documented history of nitrate intolerance was clearly an
exclusion criterion of the study. We therefore felt that these sub-
jects should be included for analysis.
Those patients who were titrated to maximal therapy may well
represent a limitation of protocol design, and this probably should
have been emphasized more clearly as one limitation of this type
of study. We believed, however, that we employed dosage sched-
ules that are commonly used in the community at large and that
comparative data at these levels would be useful. A future inves-
tigation might well address the comparison of a calcium channel
blocker with long-acting nitrates in an open label fashion where
the dosage of nitrates can be confidently advanced to "the limits
of tolerance" without fear of jeopardizing patient comfort or safety.
Finally, in response to the question of costs of respective drug
therapies, there is little or no argument that use of any of the
calcium channel blocking agents is more costly than conventional
therapy with long-acting nitrates. This fact, however, has not
dampened any of the enthusiasm for these agents nor has it pre-
cluded their widespread use. Perhaps not cost, but cost-effective-
ness, should also be addressed in future clinical trials.
JOHN MORSE, MD, FACC
Mercy Hospital & Medical Center
San Diego, California 92103
RICHARD W. NESTO, MD
New England Deaconess Hospital
Harvard Medical School
Boston, Massachusetts 02215
Closed Chest Catheter Ablation of an
Accessory Pathway in a Patient
With Permanent Junctional
Reciprocating Tachycardia
Gang et al. (I) describe successful catheter ablation of the acces-
sory pathway in the permanent form of junctional reciprocating
tachycardia. We disagree that theirs is "the first report of suc-
cessful application of the procedure in this rhythm disorder,"
because a similar report has been published (2). In addition, we
believe that some concepts concerning the initiating mechanisms
of this arrhythmia, as reported in the article, should be modified.
Our previous report (3), which is quoted by Gang et aI., dem-
onstrates that several mechanisms other than critical acceleration
of the atrial rate can be responsible for the tachycardia initiation.
Thus, we observed initiation of permanent junctional reciprocating
tachycardia without any apparent antecedent event or after an atrial
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Reply
At the time of submission of our manuscript, we were not aware
of a previous English language report of a successful catheter
ablation of an accessory pathway in a patient with the' 'permanent"
form of AV reciprocating tachycardia. Clearly, such a report had
already been published in the Italian cardiologic literature. For this
oversight, we offer our apology.
We certainly accept the comments of Monda et al. regarding
mechanisms of initiation of tachycardia in patients with permanent
junctional reciprocating tachycardia. Our introductory comments
reviewed the common mode of initiation of the tachycardia (ac-
celeration of the atrial rate prior to onset of the tachycardia), which
constitutes a sufficient but by no means necessary condition for
the onset of the tachycardia. This was invariably the way in which
the tachycardia was initiated in our patient. Our comments do not
exclude other modes of tachycardia initiation. Regardless of the
way the tachycardia is described, we are gratified that both patients
appear to have been cured of their troublesome tachycardias. In
our case, the follow-up period has now extended to 17 months
without a single recurrence of the tachycardia.
ELI S. GANG, MD, FACC
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